Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.

Transplant Infectious Disease : an Official Journal of the Transplantation Society
Eveline HofmannCédric Hirzel

Abstract

Ganciclovir (GCV)-resistant cytomegalovirus (CMV) infection is a common problem among solid organ transplant (SOT) recipients without prior CMV immunity (CMV D+/R-). GCV-resistant CMV represents a particular challenge for CMV management. Letermovir is a recently licensed antiviral agent for primary CMV prophylaxis in allogenic hematopoietic stem cell transplant (HSCT) recipients. Given the favorable safety profile and its oral bioavailability letermovir may be considered a valuable off-label option for secondary prophylaxis of GCV-resistant CMV in SOT recipients. Here, we describe our experience with letermovir as secondary prophylaxis for GCV-resistant CMV in two renal transplant recipients and review the literature in regard of previously published cases. Letermovir resistance emerged after a few months of secondary prophylaxis in the two renal transplant recipients. In both cases, the previously described UL56 C325Y letermovir resistance mutation was detected. In vitro studies of letermovir suggest a relatively low genetic barrier to resistance. Therefore, caution is warranted when using letermovir as secondary prophylaxis for GCV-resistant CMV infection.

References

May 13, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Wim LemahieuYves Vanrenterghem
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·Sunwen ChouGail I Marousek
Oct 22, 2010·The Journal of Antimicrobial Chemotherapy·Sébastien HantzUNKNOWN French CMV Resistance Survey Study Group
Sep 11, 2014·Transplantation·Timothy SullivanShirish Huprikar
Dec 11, 2014·Transplant Infectious Disease : an Official Journal of the Transplantation Society·J P GagermeierR B Love
Apr 3, 2016·Transplant Infectious Disease : an Official Journal of the Transplantation Society·P G YoungM G Ison
Oct 3, 2017·Clinical Pharmacology in Drug Development·Dirk KropeitHolger Zimmermann
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bradley J GardinerDavid R Snydman
Dec 31, 2017·Drugs·Esther S Kim
Jan 31, 2018·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Brett PierceMichael G Ison
Mar 16, 2018·Current Infectious Disease Reports·Michelle K YongOriol Manuel
Mar 30, 2018·Transplantation·Camille N KottonUNKNOWN The Transplantation Society International CMV Consensus Group
May 26, 2018·Current Opinion in Organ Transplantation·Raymund R Razonable
Jul 11, 2018·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Pearlie P ChongSonia Garg
Jan 16, 2019·Antimicrobial Agents and Chemotherapy·Nicholas TurnerCameron R Wolfe
Sep 6, 2019·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Shambhu AryalChristopher King
Jan 31, 2020·Transplantation·Pakpoom PhoompoungAtul Humar
Feb 9, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christine RobinCatherine Cordonnier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Transplant Infectious Disease : an Official Journal of the Transplantation Society
Shambhu AryalChristopher King
European Journal of Case Reports in Internal Medicine
Uta S KoepfPhilipp Lutz
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Tobias VeitNikolaus Kneidinger
© 2021 Meta ULC. All rights reserved